FoxC1/2 (K138) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
FoxC1/2 (K138) Peptide Applications :
Blocking Background :
FOXC2 is a member of forkhead/winged helix transcription factor family whose members serve as key regulators in embryogenesis and cell differentiation. FOXC2 functions as a key regulator of adipocyte metabolism by increasing the sensitivity of the β-adrenergic-cAMP-protein kinase A (PKA) signaling pathway through alteration of adipocyte PKA holoenzyme composition. Increased FOXC2 levels, induced by high fat diet, seem to counteract most of the symptoms associated with obesity. FOXC2 expression is also associated with the early stage of chondrogenic differentiation both in vivo and in vitro. FOXC2 haploinsufficiency results in Lymphedema-distichiasis (LD), an autosomal dominant disorder that classically presents as lymphedema of the limbs and double rows of eyelashes (distichiasis). Mutant mice null for FOXC2 show defects in axial and cranial skeletogenesis, suggesting a requirement of FOXC2 for skeletal tissue development. Alternative Name :
FKHL7; FREAC3; FOXC1 Swiss-Prot :
Q12948/Q99958 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide FoxC1/2 (K138). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2300 FoxC1/2 (K138) pAb.
FoxC1/2 (K138) Peptide Applications :
Blocking Background :
FOXC2 is a member of forkhead/winged helix transcription factor family whose members serve as key regulators in embryogenesis and cell differentiation. FOXC2 functions as a key regulator of adipocyte metabolism by increasing the sensitivity of the β-adrenergic-cAMP-protein kinase A (PKA) signaling pathway through alteration of adipocyte PKA holoenzyme composition. Increased FOXC2 levels, induced by high fat diet, seem to counteract most of the symptoms associated with obesity. FOXC2 expression is also associated with the early stage of chondrogenic differentiation both in vivo and in vitro. FOXC2 haploinsufficiency results in Lymphedema-distichiasis (LD), an autosomal dominant disorder that classically presents as lymphedema of the limbs and double rows of eyelashes (distichiasis). Mutant mice null for FOXC2 show defects in axial and cranial skeletogenesis, suggesting a requirement of FOXC2 for skeletal tissue development. Alternative Name :
FKHL7; FREAC3; FOXC1 Swiss-Prot :
Q12948/Q99958 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide FoxC1/2 (K138). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2300 FoxC1/2 (K138) pAb.
Blocking peptide available as BS2300PP